Alzheimer’s Drug Discovery Foundation

Financial market conditions are beginning to improve for biopharmaceutical companies raising money to fund research and development programs, thanks in large part to an increase in mergers and acquisi

Venture capital funding for biopharmaceutical companies overall may be down in 2023, but that does not mean that investors have stopped placing big bets on the industry. Three companies announced rece

Eisai Co., Ltd. and its partner Biogen, Inc. crossed over the biggest barrier in their quest to commercialize Leqembi (lecanemab) now that Medicare will cover the cost of the Alzheimer’s disease dr

It may not be as easy for private biopharmaceutical companies to raise a new venture capital round in 2023 as it was during the past few years, but VC firms have brought in an impressive amount out ca